Want to see CLDI full AI Analyst Report?
Top Page
Calidi Biotherapeutics
(CLDI)
Select Model
Select Model
Rating:42Neutral
Price Target:
$1.50
▲(14.50% Upside)
Action:Reiterated
Date:08/17/26
The score is driven primarily by weak financial performance (minimal revenue, persistent losses, and ongoing cash burn) and bearish technicals (price below key moving averages with negative MACD). Offsetting factors include improved leverage on the balance sheet and generally positive recent operational/regulatory updates, though governance actions that enable share-structure changes and expanded equity incentives temper the upside.
Positive Factors
Regulatory path for CLD-401
Positive FDA alignment reduces uncertainty around development requirements and supports progression toward first-in-human studies, creating a clearer regulatory path for Calidi’s lead oncology candidate.
Negative Factors
No commercial revenue
Calidi has no established commercial revenue base to fund research and development. Persistent operating losses leave financial performance dependent on successful clinical advancement and future external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory path for CLD-401
Positive FDA alignment reduces uncertainty around development requirements and supports progression toward first-in-human studies, creating a clearer regulatory path for Calidi’s lead oncology candidate.
Read all positive factors
Calidi Biotherapeutics (CLDI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.49M
Dividend YieldN/A
Average Volume (3M)164.15K
Price to Earnings (P/E)―
Beta (1Y)1.08
Revenue GrowthN/A
EPS Growth53.95%
CountryUS
Employees29
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-54.14
Shares Outstanding2,584,184
10 Day Avg. Volume193,319
30 Day Avg. Volume164,153
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.34
Price to Sales (P/S)0.00
P/FCF Ratio-0.24
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-88.32
Revenue Forecast (FY)N/A
Calidi Biotherapeutics Business Overview & Revenue Model
Company Description
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (d...
How the Company Makes Money
null...
Calidi Biotherapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 45.00K | 449.00K |
| Gross Profit | -426.00K | -1.65M | 0.00 | -1.26M | -229.00K | 355.00K |
| EBITDA | -16.06M | -18.19M | -19.73M | -24.20M | -25.00M | -9.45M |
| Net Income | -17.47M | -19.91M | -22.14M | -29.22M | -25.43M | -10.93M |
Balance Sheet | ||||||
| Total Assets | 7.20M | 8.86M | 14.18M | 10.02M | 2.60M | 3.39M |
| Cash, Cash Equivalents and Short-Term Investments | 4.07M | 5.60M | 9.59M | 2.05M | 372.00K | 2.14M |
| Total Debt | 1.34M | 2.56M | 7.04M | 7.24M | 5.99M | 5.18M |
| Total Liabilities | 4.07M | 5.10M | 12.21M | 18.25M | 53.04M | 26.00M |
| Stockholders Equity | 3.13M | 3.76M | 1.53M | -8.23M | -50.44M | -22.61M |
Cash Flow | ||||||
| Free Cash Flow | -17.81M | -21.41M | -19.71M | -27.57M | -13.64M | -7.98M |
| Operating Cash Flow | -17.75M | -21.29M | -19.69M | -26.98M | -13.21M | -7.77M |
| Investing Cash Flow | -144.00K | -170.00K | -16.00K | -478.00K | -494.00K | -215.00K |
| Financing Cash Flow | 16.81M | 17.46M | 27.36M | 29.04M | 12.09M | 9.81M |
Calidi Biotherapeutics Technical Analysis
Negative
1.31
Price Trends
1.92
Negative
2.63
Negative
9.17
Negative
Market Momentum
-0.17
Negative
37.56
Neutral
25.26
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLDI, the sentiment is Negative. The current price of 1.31 is below the 20-day moving average (MA) of 1.53, below the 50-day MA of 1.92, and below the 200-day MA of 9.17, indicating a bearish trend. The MACD of -0.17 indicates Negative momentum. The RSI at 37.56 is Neutral, neither overbought nor oversold. The STOCH value of 25.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLDI.
Calidi Biotherapeutics Risk Analysis
Calidi Biotherapeutics disclosed 85 risk factors in its most recent earnings report. Calidi Biotherapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Calidi Biotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $15.60M | -0.34 | -162.83% | ― | ― | 45.78% | |
43 Neutral | $4.51M | -0.27 | -64.10% | ― | ― | 71.38% | |
42 Neutral | $3.49M | -0.02 | -438.03% | ― | ― | 53.95% | |
39 Underperform | $4.75M | >-0.01 | 764.53% | ― | 135.52% | 85.50% |
* Healthcare Sector Average
CLDI
Calidi Biotherapeutics
1.30
-26.06
-95.25%
GLMD
Galmed Pharmaceuticals
4.31
-6.73
-61.01%
JAGX
Jaguar Animal Health
0.87
-55.14
-98.46%
ADIL
Adial Pharmaceuticals
5.69
-4.03
-41.46%
CDIO
Cardio Diagnostics Holdings
1.87
-1.92
-50.66%
Calidi Biotherapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresRegulatory Filings and Compliance
Calidi Biotherapeutics Reports Quarterly Results and Pipeline Progress
Positive
Aug 13, 2026
On August 13, 2026, Calidi Biotherapeutics reported financial results for the quarter ended June 30, 2026, alongside operational updates that underscore progress in its RedTail virotherapy platform. The company received positive pre-IND feedback f...
Delistings and Listing ChangesShareholder MeetingsStock Split
Calidi Biotherapeutics Implements Reverse Stock Split on NYSE
Neutral
Jul 31, 2026
On June 12, 2026, Calidi Biotherapeutics stockholders approved a 1-for-16 reverse stock split of the company’s issued and outstanding common stock. The measure was implemented as a proactive step to raise the per-share trading price and supp...
Business Operations and Strategy
Calidi Biotherapeutics Plans Relocation Through New Lease Agreements
Neutral
Jul 17, 2026
On July 10, 2026, Calidi Biotherapeutics entered into a Lease Termination Agreement with 4475 Executive Drive LLC to end its existing lease for office and laboratory space at 4475 Executive Drive in San Diego, which had originally been scheduled t...
Business Operations and StrategyExecutive/Board Changes
Calidi Biotherapeutics Expands Board With New Independent Director
Positive
Jun 23, 2026
On June 17, 2026, Calidi Biotherapeutics appointed industry veteran Corazon (Corsee) Sanders, Ph.D., as a Class III independent director with a term running through the 2029 annual meeting. She also joined the Board’s Audit Committee, replac...
Business Operations and StrategyExecutive/Board ChangesShareholder MeetingsStock Split
Calidi Biotherapeutics Stockholders Approve Key Governance Measures
Positive
Jun 18, 2026
On June 12, 2026, Calidi Biotherapeutics held its 2026 Annual Meeting of Stockholders, where a quorum was reached with about 55% of eligible shares represented, and all proposals on the agenda were approved. Stockholders elected Scott Leftwich as ...
Private Placements and FinancingRegulatory Filings and Compliance
Calidi Biotherapeutics Amends Warrant in Private Placement
Neutral
May 29, 2026
On May 28, 2026, Calidi Biotherapeutics, Inc. amended and restated a previously issued warrant to an accredited investor, allowing the purchase of up to 17,391,304 unvested shares of common stock at an exercise price of $0.23 in a private placemen...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.